4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS
The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia.
1 - 56 . (canceled)
57 . A compound of Formula (II):
wherein
X is selected from a covalent bond, S, or O;
Y is S or O;
- - - - -W- - - - - represents a group selected from —CH═, —CH 2 —, —CH 2 —CH 2 —, —CH 2 —CH═, and —CH═CH—;
Z is selected from O, CH, and CH 2 , provided when Y is O, Z is O;
R 1 and R 2 are independently selected from H, C 1-3 alkyl, C 1-3 alkoxy, halo, and NR a R b wherein R a and R b are independently H or C 1-3 alkyl;
R 3 and R 4 are independently selected from H, halo, cyano, hydroxy, acetyl, C 1-5 alkyl, C 1-4 alkoxy, and NR c R d wherein R c and R d are independently H or C 1-3 alkyl, provided that R 3 and R 4 are not both H;
n is 1 or 2;
or a pharmaceutically acceptable salt thereof.
58 . The compound of claim 57 wherein X is S or O.
59 . The compound of claim 58 wherein X is O.
60 . The compound of claim 57 wherein X is a covalent bond.
61 . The compound of claim 57 wherein Y is O.
62 . The compound of claim 57 wherein Y is S.
63 . The compound of claim 57 wherein Z is O.
64 . The compound of claim 57 wherein Z is CH or CH 2 .
65 . The compound of claim 57 wherein - - - - -W- - - - - represents —CH 2 — or CH 2 —CH 2 —.
66 . The compound of claim 65 wherein - - - - -W- - - - - represents —CH 2 —.
67 . The compound of claim 57 wherein - - - - -W- - - - - represents —CH═, —CH 2 —CH═, or —CH═CH—.
68 . The compound of claim 57 wherein R 3 and R 4 are independently selected from H, halo, cyano, C 1-4 alkyl, and C 1-3 alkoxy.
69 . The compound of claim 57 wherein R 1 and R 2 are independently selected from H, C 1-3 alkyl, C 1-3 alkoxy, F, Cl, and Br.
70 . The compound of claim 69 wherein R 1 and R 2 are independently selected from H, methyl, methoxy, F and Cl.
71 . The compound of claim 57 wherein R 3 and R 4 are independently selected from H, halo, cyano, hydroxy, C 2-4 acyl, C 1-4 alkyl, and C 1-3 alkoxy.
72 . The compound of claim 71 wherein R 3 is independently selected from H, F, Cl, methyl, and methoxy.
73 . The compound of claim 71 wherein R 4 is independently selected from F, Cl, methyl, methoxy, trifluoromethyl, fluoromethyl, difluoromethyl, chlorodifluoromethyl, dichlorofluoromethyl, fluoromethoxy, difluoromethoxy, chlorodifluoromethoxy, dichlorofluoromethoxy and trifluoromethoxy.
74 . The compound of claim 57 wherein R 3 is selected from methyl, methoxy, H, Cl, Br, I, OH, —CH(CF 3 ) 2 , CF 3 , —OCF 3 , —N(CH 3 ) 2 , —O—CH 2 COOH, and —COCH 3 , and R 4 is selected from H, Cl, and methyl.
75 . The compound of claim 57 wherein R 3 is selected from H, F, Cl, methyl, and methoxy, and R 4 is selected from F, Cl, methyl, fluoromethyl, difluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethyl, trifluoromethoxy, and methoxy.
76 . The compound of claim 57 wherein R 1 is selected from H, CF 3 , methyl, Cl, and methoxy, and R 2 is selected from H, Cl, and methyl.
77 - 92 . (canceled)
94 . A pharmaceutical composition comprising a compound of of claims 57 .
95 . (canceled)